PDS Biotechnology (PDSB) Income from Continuing Operations (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Income from Continuing Operations came in at 73201.0 in Q4 2025, up 99.08% YoY from 36769.73 in Q4 2024, and up 99.19% on a QoQ basis from 9009411.0 in Q3 2025.
PDS Biotechnology (PDSB) Income from Continuing Operations (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Income from Continuing Operations data on file, last reported at 73201.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 99.08% year-over-year to 73201.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27005787.0 (up 28.2% YoY) and the FY2025 annual result came in at 28175607.0, up 25.09% from the prior year.
- Income from Continuing Operations advanced to 73201.0 in Q4 2025, from 9009411.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 73201.0 in Q4 2025 to a low of 19138778.0 in Q4 2022.
- A 5-year average of 8671663.35 and a median of 8749189.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 888.1% — and 2025, when it surged 99.08%.
- Tracing PDSB's Income from Continuing Operations over 5 years: stood at 6319962.0 in 2021, then plunged by 202.83% to 19138778.0 in 2022, then surged by 43.06% to 10898216.0 in 2023, then gained by 27.03% to 7952352.0 in 2024, then surged by 99.08% to 73201.0 in 2025.
- The last three Income from Continuing Operations figures came in at 73201.0 (Q4 2025), 9009411.0 (Q3 2025), and 9434208.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | -9.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.75 Mn |
| Dec 31, 2025 | -73,201.00 |
| Sep 30, 2025 | -9.01 Mn |
| Jun 30, 2025 | -9.43 Mn |
| Mar 31, 2025 | -8.49 Mn |
| Dec 31, 2024 | -7.95 Mn |
| Sep 30, 2024 | -10.73 Mn |
| Jun 30, 2024 | -8.33 Mn |
| Mar 31, 2024 | -10.60 Mn |
| Dec 31, 2023 | -10.90 Mn |
| Sep 30, 2023 | -10.85 Mn |
| Jun 30, 2023 | -11.53 Mn |
| Mar 31, 2023 | -9.66 Mn |
| Dec 31, 2022 | -19.14 Mn |
| Sep 30, 2022 | -7.42 Mn |
| Jun 30, 2022 | -5.82 Mn |
| Mar 31, 2022 | -14.92 Mn |
| Dec 31, 2021 | -6.32 Mn |
| Sep 30, 2021 | -6.96 Mn |
| Jun 30, 2021 | -588,931.00 |